Dirk Strumberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dirk Strumberg has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alma Aslan
Agaplesion Bethesda Ulm, Geriatric Centre Ulm/Alb-Donau, Ulm, Germany, Germany
1 shared publication - Amin Taha Turki
Department of Hematology and Oncology, Marien Hospital Herne, University Hospital, Ruhr University Bochum, Herne, Germany, Germany
1 shared publication - Beate Schultheis
Department of Hematology and Oncology, Marien Hospital Herne, University of Bochum, 44627 Herne, Germany
1 shared publication - Chantal Giehl
Department of Geriatric Medicine, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany
1 shared publication - Christian Baues
Department of Radiation Oncology, Marien Hospital Herne, University Hospital, Ruhr University Bochum, Herne, Germany, Germany
1 shared publication - Dennis Akuamoa-Boateng
Department of Radiation Oncology, Marien Hospital Herne, University Hospital, Ruhr University Bochum, Herne, Germany, Germany
1 shared publication
Latest Publications
- Open Access
- 7 January 2026
- Published by MDPI AG in Preprints.org
Integration of Geriatric Assessment—Guided Care Plan Modifications and Interventions into Clinical Paths of Older Adults with Cancer (GORILLA): A Feasibility Approach
Background/Objectives: A comprehensive geriatric assessment (CGA) was demon-strated to reduce treatment-related toxicities CTCAE III-V° in older adults with cancer undergoing systemic cancer treatments. However, practical implementation of this important procedure is insufficient. To evaluate the feasibility of implementing CGA into routine care and multidisciplinary tumor boards (MDTs) in Germany, we per-formed this bicentric feasibility trial. Methods: Patients ≥65 years with positive geriatric screening (G8< 15 points) and all patients ≥70 years received CGA as part of their routine care. Results were presented during MDT discussions to derive treatment recommendations. After CGA, patients were asked for trial participation which included data analysis and a telephone fol-low-up after 3 months. Physicians participating in the MDT were asked about the added value of CGA presentation. Primary endpoint was the estimation of patient’s willing-ness to participate with an accuracy of ± 7.5% to inform design for a later effectiveness trial. Results: 75 patients received CGA. Of those, 72 (96%) agreed to participate (95% confi-dence interval, [0.8875; 0.9917]). With an accuracy of estimating the willingness to par-ticipate of < |7.5%|, the primary endpoint was reached. The median age was 76.6 years (range: 69-92 years). A member of the geriatric team attended 2/3 of the MDT meetings. Physicians rated the integration of CGA results predominantly as useful. Conclusions: Integration of CGA into routine care of older cancer patients is feasible but will likely require adequate geriatric staffing per center. A larger implementation study, evaluating efficacy and cost effectiveness in the German healthcare system, is necessary.
- 7 January 2026
- Published by MDPI AG in Preprints.org
Open AccessIntegration of Geriatric Assessment—Guided Care Plan Modifications and Interventions into Clinical Paths of Older Adults with Cancer (GORILLA): A Feasibility Approach
Background/Objectives: A comprehensive geriatric assessment (CGA) was demon-strated to reduce treatment-related toxicities CTCAE III-V° in older adults with cancer undergoing systemic cancer treatments. However, practical implementation of this important procedure is insufficient. To evaluate the feasibility of implementing CGA into routine care and multidisciplinary tumor boards (MDTs) in Germany, we per-formed this bicentric feasibility trial. Methods: Patients ≥65 years with positive geriatric screening (G8< 15 points) and all patients ≥70 years received CGA as part of their routine care. Results were presented during MDT discussions to derive treatment recommendations. After CGA, patients were asked for trial participation which included data analysis and a telephone fol-low-up after 3 months. Physicians participating in the MDT were asked about the added value of CGA presentation. Primary endpoint was the estimation of patient’s willing-ness to participate with an accuracy of ± 7.5% to inform design for a later effectiveness trial. Results: 75 patients received CGA. Of those, 72 (96%) agreed to participate (95% confi-dence interval, [0.8875; 0.9917]). With an accuracy of estimating the willingness to par-ticipate of < |7.5%|, the primary endpoint was reached. The median age was 76.6 years (range: 69-92 years). A member of the geriatric team attended 2/3 of the MDT meetings. Physicians rated the integration of CGA results predominantly as useful. Conclusions: Integration of CGA into routine care of older cancer patients is feasible but will likely require adequate geriatric staffing per center. A larger implementation study, evaluating efficacy and cost effectiveness in the German healthcare system, is necessary.
- Open Access
Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study
Background: Atu027 is a liposomally formulated short interfering RNA with anti-metastatic activity, which silences the expression of protein kinase N3 (PKN3) in the vascular endothelium. This trial was designed to assess the safety, pharmacokinetics and efficacy of Atu027 in combination with gemcitabine in advanced pancreatic carcinoma (APC). Methods: In total, 23 patients (pts) with inoperable APC were randomly assigned to gemcitabine combined with two different Atu027 schedules (0.235 mg/kg once weekly vs. 0.235 mg/kg twice weekly). ClinicalTrials.gov Identifier: NCT01808638. Results: The treatment was well-tolerated. There were Grade 3 adverse events (AEs) in 9/11 pts (arm 1) and 11/12 pts (arm 2), while Grade 4 AEs were reported for two pts in each arm. The AEs were mainly laboratory abnormalities without clinical significance. The median progression-free survival reached statistical significance in patients who had metastatic disease (1.6 vs. 2.9 months, p = 0.025). Disease control during treatment was achieved in 4/11 pts (arm 1) and in 7/12 pts (arm 2). Pts in arm 1 experienced stable global health status while pts in arm 2 reported improvement. Conclusions: Combining Atu027 with gemcitabine is safe and well tolerated. In pts with metastatic APC, twice-weekly Atu027 is associated with significantly improved outcomes. Our clinical results support the significant involvement of the vascular endothelium in the spread of cancer, and thus the further investigation of its target role.
Open AccessSafety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study
Background: Atu027 is a liposomally formulated short interfering RNA with anti-metastatic activity, which silences the expression of protein kinase N3 (PKN3) in the vascular endothelium. This trial was designed to assess the safety, pharmacokinetics and efficacy of Atu027 in combination with gemcitabine in advanced pancreatic carcinoma (APC). Methods: In total, 23 patients (pts) with inoperable APC were randomly assigned to gemcitabine combined with two different Atu027 schedules (0.235 mg/kg once weekly vs. 0.235 mg/kg twice weekly). ClinicalTrials.gov Identifier: NCT01808638. Results: The treatment was well-tolerated. There were Grade 3 adverse events (AEs) in 9/11 pts (arm 1) and 11/12 pts (arm 2), while Grade 4 AEs were reported for two pts in each arm. The AEs were mainly laboratory abnormalities without clinical significance. The median progression-free survival reached statistical significance in patients who had metastatic disease (1.6 vs. 2.9 months, p = 0.025). Disease control during treatment was achieved in 4/11 pts (arm 1) and in 7/12 pts (arm 2). Pts in arm 1 experienced stable global health status while pts in arm 2 reported improvement. Conclusions: Combining Atu027 with gemcitabine is safe and well tolerated. In pts with metastatic APC, twice-weekly Atu027 is associated with significantly improved outcomes. Our clinical results support the significant involvement of the vascular endothelium in the spread of cancer, and thus the further investigation of its target role.